Sun Pharma completes allotment of ₹7,816 crore NCDs via private placement
Sun Pharma.Inds. · Pharmaceuticals & Biotechnology
What the filing says
- Allotted rated, listed, unsecured, redeemable non-convertible debentures in Series A (₹2,003 crore) and Series B (₹5,813 crore) on 26 October 2026
- Series A Debentures bear 8.05% p.a. interest, Series B Debentures bear 8.20% p.a., with scheduled redemption on 27 October 2031
- Series A Debentures include a put option exercisable on 27 March 2028; NCDs to be listed on BSE and NSE
Why it's rated notable: amount is ₹500 crore or more
Original filing
Announcement under Regulation 30 (LODR)-Allotment
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Electrical Equipment
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Sun Pharma.Inds.
- Fundraise / allotmentNotableSun Pharma board approves NCDs up to ₹10,000 crore; independent director Doshi resigns
- Fundraise / allotmentNotableSun Pharma board to meet on 12 Oct 2026 to approve NCD issuance up to ₹15,000 Cr
Other fundraise / allotment filings this fortnight
- Motilal Oswal Financial Services Q2 & H1 FY27 results and corporate updates
- Lloyds Metals and Energy Ltd allots USD 130 million senior secured floating rate bonds
- OnEMI Technology board approves rights investment in subsidiary Si Creva Capital
- OnEMI Technology Solutions approves ₹624.15 crore investment in Si Creva Capital Services
- Hexaware Q3CY26 profit INR 4,294 Mn, up 16.1% YoY; new CEO, board changes
- JSW Energy Limited announces Q2 & H1 FY27 results and fund raising plans
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.